Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
49 hedge funds and large institutions have $103M invested in Adaptimmune Therapeutics in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 12 closing their positions.
0.02% less ownership
Funds ownership: 10.85% → 10.84% (-0.02%)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
17% less funds holding
Funds holding: 59 → 49 (-10)
62% less capital invested
Capital invested by funds: $274M → $103M (-$171M)
83% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 12
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$892K |
| 2 |
Morgan Stanley
New York
|
+$574K |
| 3 |
Man Group
London,
United Kingdom
|
+$492K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$225K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$946K |
| 2 |
BAMCO Inc
New York
|
-$694K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$409K |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$355K |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$354K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| – | -$26K | -6,700 | Closed |
|
52
State of Tennessee, Department of Treasury
Nashville,
Tennessee
| – | -$24K | -6,085 | Closed |
|
|
PCM
53
Prelude Capital Management
New York
| – | -$9K | -2,204 | Closed |
|
54
KBC Group
Brussels,
Belgium
| – | -$4.04K | -1,730 | -91% |
|
55
Simplex Trading
Chicago,
Illinois
| – | -$3.13K | -1,340 | -95% |
|
|
ACS
56
Archford Capital Strategies
Swansea,
Illinois
| – | -$4K | -1,000 | Closed |
|
|
RE
57
RBC Europe
London,
United Kingdom
| – | -$2.41K | -600 | Closed |
|
|
PA
58
Parallel Advisors
San Francisco,
California
| – | -$734 | -314 | Closed |
|
ADAP Hedge Fund Activity: Q3 2019 in Review
49 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2019, worth a combined $103M — down 62% from $274M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ADAP and 2 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 12 added.
The largest buyer was Renaissance Technologies, adding an estimated $892K. The largest seller was Millennium Management, cutting an estimated $946K.
- 49 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2019, down from 59 in Q2 2019.
- Funds reported $103M of Adaptimmune Therapeutics stock for Q3 2019, down 62% quarter-over-quarter.
- 2 funds opened new Adaptimmune Therapeutics positions in Q3 2019 and 12 closed out, a net change of -10 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2019 was Renaissance Technologies, an estimated $892K added.
- The largest Adaptimmune Therapeutics seller in Q3 2019 was Millennium Management, an estimated $946K sold.
Based on aggregated 13F filings for Q3 2019.